Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies
Sponsor: Consorzio per Valutazioni Biologiche e Farmacologiche
This PHASE3 trial investigates Chronic Iron Overload and is currently completed. Consorzio per Valutazioni Biologiche e Farmacologiche leads this study, which shows 12 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jun 2021 — Dec 2022 [monthly]
Completed PHASE3
-
May 2021 — Jun 2021 [monthly]
Completed PHASE3
-
Jan 2021 — May 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE3
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Consorzio per Valutazioni Biologiche e Farmacologiche
- European Commission
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alexandria, Egypt , Athens, Greece , Bari, Italy , Cagliari, Italy , Cairo, Egypt , Catania, Italy , Cosenza, Italy , Florence, Italy , Lentini, Italy , London, United Kingdom and 11 more locations